Research ArticleSPECIAL CONTRIBUTION

Advances in Pharmacologic Stress Agents: Focus on Regadenoson

Sara G. Johnson and Scott Peters
Journal of Nuclear Medicine Technology September 2010, 38 (3) 163-171; DOI: https://doi.org/10.2967/jnmt.109.065581

Article Figures & Data

Figures

  • FIGURE 1.
    FIGURE 1.

    Reversal time of coronary vasodilation in high-affinity and low-affinity A2A agonists (21,34). Ki = dissociation constant of inhibitor; t0.5 = time to 50% reversal if coronary conductance increases in rat isolated perfused hearts. (Reprinted with permission of (34).)

  • FIGURE 2.
    FIGURE 2.

    Agreement rates of adenosine–adenosine and adenosine–regadenoson stress MPI studies with respect to extent of ischemia in combined ADVANCE MPI 1 and 2 study population (41). Data are median ± SE.

  • FIGURE 3.
    FIGURE 3.

    Administration of regadenoson. *Aminophylline may be given 1–2 min after injection of isotope to reverse persistent or severe side effects.

Tables

  • TABLE 1.

    Definitions of Common Pharmacologic Terms

    TermDefinition
    AgonistA molecule that binds to a receptor and elicits a response by the cell
    AntagonistA molecule that binds to a receptor, but rather than causing a response, blocks the binding of an agonist, so preventing the response
    AffinityThe tightness with which an agonist/antagonist binds to a receptor (described using the dissociation constant)
    SelectivityActivity of an agonist against a limited number of receptors
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section